Actively Recruiting
Drug Excretion in Breast Milk
Led by University of Washington · Updated on 2024-08-06
50
Participants Needed
1
Research Sites
251 weeks
Total Duration
On this page
Sponsors
U
University of Washington
Lead Sponsor
E
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a prospective, non-randomized, phase I study design evaluating the in vivo activities and expression of OCT1 and BCRP in mammary gland of lactating women at three time points postpartum.
CONDITIONS
Official Title
Drug Excretion in Breast Milk
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Healthy postpartum women
- Aged 18 to 50 years
- Able to provide written informed consent
You will not qualify if you...
- Received cimetidine within 3 days before each study day
- Known allergy or hypersensitivity to cimetidine
- Taking medications that interact with cimetidine or affect OCT1, BCRP, or key liver enzymes
- Taking BCRP or OCT1 inhibitors or inducers
- Known kidney disease with impaired renal function (serum creatinine > 1.2 mg/dL)
- Known significant liver disease (ALT more than 2 times upper limit of normal)
- Unable to fast for 4 hours before each study day
- Tobacco or nicotine product use
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Washington
Seattle, Washington, United States, 98195
Actively Recruiting
Research Team
M
Mary Hebert, PharmD, FCCP
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
BASIC_SCIENCE
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here